<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01551524</url>
  </required_header>
  <id_info>
    <org_study_id>AZPO2-CLT-001</org_study_id>
    <secondary_id>2011-000295-34</secondary_id>
    <nct_id>NCT01551524</nct_id>
  </id_info>
  <brief_title>Phase I Study of mPEG-R-Crisantaspase Given IV</brief_title>
  <official_title>A Dose Escalation Phase I Study of Asparec®(mPEG-R-Crisantaspase) Administered as Intravenous (IV) Infusion in Patients With Relapsed or Refractory Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EUSA SAS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jazz Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open label, multicenter study with a dose escalation of Asparec®&#xD;
      administered once every two to four weeks for two administrations. The primary objective of&#xD;
      this study is to determine the Maximum Tolerated Dose following one single dose of Asparec&#xD;
      when administered in a population of patients with relapsed or refractory hematological&#xD;
      malignancies, as measured by Dose Limiting toxicities. There are secondary objectives which&#xD;
      are to evaluate the safety of Asparec and to determine the PK profile as assessed by&#xD;
      measurement of plasma L-asparaginase enzymatic activity following single and repeated doses&#xD;
      of Asparec. Patients response rate will be evaluated and Anti-Asparec antibodies will be&#xD;
      measured.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Planned sample size: Up to 36 evaluable subjects will be enrolled in the study: a maximum of&#xD;
      30 subjects for the dose escalation phase and up to a maximum of 12 patients in the expansion&#xD;
      phase.&#xD;
&#xD;
      Inclusion criteria consists of:&#xD;
&#xD;
      Patients with any relapsed or refractory hematological malignancy, for which standard&#xD;
      curative or life prolonging treatment does not exist, or is no longer effective or tolerable.&#xD;
&#xD;
      For the following hematological malignancies, patients must have received at least: Low rade&#xD;
      NHL: 3 prior lines of therapy, ALL, aggressive NHL and other hematological malignancies: 2&#xD;
      prior lines of therapy, Aged 18 to 50 years and ECOG performance status of 1, 1 or 2.&#xD;
&#xD;
      All patients will be treated with Asparec once every two to four weeks for two IV&#xD;
      administrations infused in 60 minutes. Patients without Disease Progression may receive&#xD;
      additional administrations, each administration starting at least 14 days but no later than&#xD;
      28 days after the previous Asparec administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the Maximum Tolerated Dose following one single dose of mPEG-r-Crisantaspase when administered in a population of patients with relapsed or refractory hematological malignancies, as measured by Dose Limiting Toxicities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asparaginase Activity in serum</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the pharmacokinetic profile as assessed by measurement of serum L-asparaginase enzymatic activity following single and double mPEG-r-chrisantaspace doses.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Intravenous Erwinia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mPEG-r-crisantaspase</intervention_name>
    <description>IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%</description>
    <arm_group_label>Intravenous Erwinia</arm_group_label>
    <other_name>Asparec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with any relapsed or refractory hematological malignancy, for which standard&#xD;
             curative or life prolonging treatment does not exist, or is no longer effective or&#xD;
             tolerable.&#xD;
&#xD;
          -  For the following hematological malignancies, patients must have received at least:&#xD;
&#xD;
               -  Low grade NHL:&#xD;
&#xD;
                    -  3 prior lines of therapy and ALL,&#xD;
&#xD;
               -  aggressive NHL and other hematological malignancies:&#xD;
&#xD;
                    -  2 prior lines of therapy.&#xD;
&#xD;
          -  Ages 18 to 50 years and&#xD;
&#xD;
          -  ECOG performance status of 0, 1 or 2,&#xD;
&#xD;
          -  ability to understand and to sign a written informed consent and&#xD;
&#xD;
          -  have a life expectancy of greater than or equal to 90 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any active CNS disease,&#xD;
&#xD;
          -  previous greater than or equal to grade 3 allergic reaction to Erwinase,&#xD;
&#xD;
          -  patients who have experienced a greater than or equal to grade 3 allergic reaction to&#xD;
             E. coli L-asparaginase and who have never received E. chrysanthemi L-asparaginase&#xD;
             after the occurrence of this reaction,&#xD;
&#xD;
          -  WBC count greater than 20 Gica/L, any of the following laboratory abnormalities if not&#xD;
             due to hematologic malignancy (calculated creatinine clearance less than 50 mL/min,&#xD;
&#xD;
          -  serum SGOT/AST or SGPT?ALT greater than 2.5 x upper limit of normal,&#xD;
&#xD;
          -  serum total bilirubin greater than 2.0 mg/dL, except in the case of hemolytic anemia.&#xD;
&#xD;
          -  Patients cannot have a history of greater than or equal to grade 2 pancreatitis,&#xD;
&#xD;
          -  any history of allogeneic transplant,&#xD;
&#xD;
          -  receiving steroid therapy with a dose greater than 20 mg/day,&#xD;
&#xD;
          -  known HIV positive serology,&#xD;
&#xD;
          -  active hepatitis B or C,&#xD;
&#xD;
          -  any serious active disease or comorbid medical condition or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent.&#xD;
&#xD;
          -  Pregnant or lactating females or women of child bearing potential not willing to use&#xD;
             an adequate method of birth control for the duration of the study are not eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pr Gilles Salles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Lyon Sud -Chemin du Grand Revoyet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier Thomas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Lyon Sud - Chemin du Grand Revoyet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <state>Cedex</state>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux du CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>C240588.448</keyword>
  <keyword>C115.378.400</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

